Brief: Bergenbio Announces Discontinuation Of 1L Stk11m Nsclc Study And Exploration Of Strategic Alternatives
25/02/2025 19:00
Feb 25 (Reuters) - Bergenbio ASA BGBIO.OL: BERGENBIO ANNOUNCES DISCONTINUATION OF 1L STK11M NSCLC STUDY AND EXPLORATION OF STRATEGIC ALTERNATIVES BERGENBIO ASA: WILL CONSIDER OPTIONS INCLUDING, A POTENTIAL SALE, MERGER, OR OTHER STRATEGIC TRANSACTION. Source text: ID:nWkrLnGlj Further company coverage: BGBIO.OL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee